Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

DNATWO Inc
Profile last edited on: 2/27/2023      CAGE: 8NBQ0      UEI: GF3FNPVVKEL2

Business Identifier: Developer of pharmaceutical drug designed to treat cancer
Year Founded
2020
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

13451 Rand Drive
Sherman Oaks, CA 91423
   (626) 395-6053
   N/A
   N/A
Location: Single
Congr. District: 32
County: Los Angeles

Public Profile

Developer of pharmaceutical drug designed to treat cancer. The company develops a pipeline of deoxyribonucleic acid (DNA) repair inhibitor drugs to treat cancer disease and deliver new therapies toxic to tumor cells, enabling osteosarcoma, colorectal, and breast cancer patients to recover their health.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$397,221
Phase II Dollars
$0
Total Awarded
$397,221

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $397,221
Project Title: Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBC

Key People / Management

  Kenneth Schultz -- Co-Founder & Chief Executive Officer

  Judith Campbell -- Co-Founder & Chairman

  Brian Stoltz -- Co-Founder & Chief Chemist

Company News

There are no news available.